Jane Adams

Cooley advised biotechnology company Cidara Therapeutics on its exclusive worldwide licensing and collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of seasonal and pandemic influenza. Partners Jane Adams and Tanisha James led the Cooley team advising Cidara.

Under the terms of the collaboration, Cidara will be responsible for the development and manufacturing of the first influenza antiviral conjugates, CD388, into the clinic and through phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. Cidara will receive a $27 million upfront payment and will be eligible to receive up to $753 million in budgeted research and development funding and in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales. 

Cooley advised biotechnology company Cidara Therapeutics on its exclusive worldwide licensing and collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of seasonal and pandemic influenza. Partners Jane Adams and Tanisha James led the Cooley team advising Cidara.

Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases – on its agreement to sell to Bristol Myers Squibb. Barbara Borden, Marya Postner and Rowook Park led the Cooley team advising Forbius. 

San Diego – Cooley advised Ionis Pharmaceuticals on a global collaboration, option and license agreement with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the GI tract.

Pursuant to the agreement, Ionis will receive $35 million in up-front payments for three programs, including a payment to initiate human lead optimization on the first collaboration target. Isis is also eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees for the programs.

Ionis is the leader in antisense drug discovery and development, exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.

Partner Jane Adams, a member of Cooley's life sciences partnering and licensing group, led the Cooley team that advised Ionis Pharmaceuticals on the collaboration.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.